Tissue factor pathway inhibitor-2 inhibits integrin β1 activation and focal adhesion formation and suppresses peritoneal ovarian cancer dissemination in mice

Biochem Biophys Res Commun. 2024 Dec 3:736:150890. doi: 10.1016/j.bbrc.2024.150890. Epub 2024 Oct 24.

Abstract

Tissue factor pathway inhibitor-2 (TFPI2) is a Kunitz-type serine protease inhibitor and an ovarian clear cell carcinoma (CCC) biomarker. TFPI2 is expressed in several cancers and exerts tumor-suppressive effects; however, the role of TFPI2 in the CCC cell phenotype remains unclear. Therefore, in this study, we investigated the function of TFPI2 by establishing a gene knockout (KO) in ES-2 CCC cells and observed the change in phenotypes in vitro and in vivo. TFPI2 KO inhibited ES-2 cell proliferation, increased extracellular matrix protein adhesion, enhanced focal adhesion formation and activated integrin β1 cell surface clustering in vitro, and markedly increased ES-2 tumor growth and dissemination in the peritoneal cavity of a mouse xenograft model. These findings suggest a novel function of TFPI2 expression in suppressing the formation of focal adhesions in CCC cells, potentially by activating integrin β1. This function plays a role in the peritoneal growth characteristics of CCC cells.

Keywords: Dissemination; Focal adhesion; Integrin β1; Ovarian cancer; Tissue factor pathway inhibitor-2.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Female
  • Focal Adhesions* / metabolism
  • Gene Knockout Techniques
  • Glycoproteins* / genetics
  • Glycoproteins* / metabolism
  • Humans
  • Integrin beta1* / genetics
  • Integrin beta1* / metabolism
  • Mice
  • Mice, Nude
  • Ovarian Neoplasms* / genetics
  • Ovarian Neoplasms* / metabolism
  • Ovarian Neoplasms* / pathology
  • Peritoneal Neoplasms* / genetics
  • Peritoneal Neoplasms* / metabolism
  • Peritoneal Neoplasms* / pathology
  • Peritoneal Neoplasms* / secondary

Substances

  • Integrin beta1
  • tissue-factor-pathway inhibitor 2
  • Glycoproteins